GM Dallinga-Thie, A Van Tol, H Hattori, LC van Vark- … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 1505–1511 DOI 10.1007/s00125-006-0261-0
ARTICLE GM Dallinga-Thie . A. van Tol . H. Hattori . LC van Vark-van der Zee . H.
Jansen . EJG Sijbrands . on behalf of the DALI study group Plasma ... Cited by 33 - Related articles - BL Direct - All 4 versions
E Ooi, P Barrett, D Chan, G Watts - Clinical Science, 2008 - clinsci.org Abbreviations: apo, apolipoprotein; apoC-III-LpB, apoC-III associated with apoB-containing
lipoproteins; apoC-III-non-LpB, apoC-III associated with non-apoB-containing lipoproteins;
CARE, Cholesterol and Recurrent Events; CETP, cholesteryl ester transfer protein; CLAS, ... Cited by 16 - Related articles - Cached - BL Direct - All 7 versions
RM Crooke - Expert Opin. Biol. Ther., 2005 - Informa Pharma Science Hyperlipidaemia, due to elevations of low-density lipoprotein cholesterol (LDL-C) or triglycerides
(TGs), is recognised as a significant risk factor contrib- uting to the development of coronary heart
disease (CHD), the leading cause of morbidity and mortality in the Western world. Even ... Cited by 12 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org DC Chan, GF Watts, EMM Ooi, J Ji, AG … - … , and vascular biology, 2008 - Am Heart Assoc Methods and Results— The effects of atorvastatin (40 mg/d) and fenofibrate (200 mg/d) on the
kinetics of very-low density lipoprotein (VLDL)-apoC-III were investigated in a crossover trial
of 11 MetS men. VLDL-apoC-III kinetics were studied, after intravenous d 3 -leucine ... Cited by 3 - Related articles - All 6 versions
GR Hajer, GM Dallinga-Thie, LC van Vark-van der Zee, … - Atherosclerosis, 2009 - Elsevier Fasting LDL-C, RLP-C and triglycerides were lowered equally by both simvastatin 80 mg and
simvastatin/ezetimibe 10 mg/10 mg. Also postprandial plasma triglyceride levels (net
AUC-TG) were equally lowered after both treatments (5.16 ± 0.50 mmol h/l after ... Cited by 3 - Related articles - All 11 versions
J Julve… - Arteriosclerosis, Thrombosis, and Vascular Biology, 2009 - Am Heart Assoc Introduction—Apolipoprotein (apo) A-II is the second most abundant high-density lipoprotein
(HDL) apolipoprotein. We assessed the mechanism involved in the altered postprandial
triglyceride-rich lipoprotein metabolism of female human apoA-II-transgenic mice ...
KF Croom, GL Plosker - Drugs, 2005 - pt.wkhealth.com Atorvastatin 10mg daily for 4 years was effective at reducing the risk of a first major cardiovascular
event, including stroke, in a large, placebo-controlled, multicentre trial in patients with type 2
diabetes and at least one other coronary heart disease (CHD) risk factor, but without ... Related articles
AT Chan, BK Nallamothu, HS Gurm, RA Hayward, S … - Circulation, 2006 - pt.wkhealth.com Establishment of the role of pathways that lead to heritable hypercoagulable phenotypes in multifactorial
disorders such as cardiovascular diseases is complicated by the inability to adequately discern
the necessity and sufficiency of proposed mediators of hypercoagulability (Figure 1).2 ... Related articles - All 2 versions